Plenge Gen (PlengeGen Blog)

Connected by Design: How AI and Automation Are Transforming Drug Discovery at BMS

Bristol Myers Squibb (BMS) is shifting from isolated AI tools to an integrated, learning‑driven ecosystem that connects data, models, and automation across discovery and development. The company highlights its shared data backbone, AI co‑scientists, and lab‑in‑the‑loop automation as foundational layers, aiming to cut drug‑candidate timelines by 30‑50 %. Using the TYK2 inhibitor as a case study, BMS shows how AI‑enabled design‑make‑test‑analyze cycles could shrink a 5‑7‑year program to roughly 3.5 years. While components are operational, full closed‑loop feedback between bench and bedside remains a work in progress.